Major challenges limiting liver transplantation in the United States

American Journal of Transplantation

Volumn 11, Issue 9, 2011, Pages 1773-1784

  Wertheim, J A ^a   Petrowsky, H ^a   Saab, S ^a   Kupiec Weglinski, J W ^a   Busuttil, R W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Donation after cardiac death; donor organ shortage; extended criteria donor; hepatitis C; hepatocellular carcinoma; liver transplantation; living donor liver transplantation; split liver transplantation

Indexed keywords

ALPHA FETOPROTEIN; ALPHA INTERFERON; BIOLOGICAL MARKER; BOCEPREVIR; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; ERYTHROPOIETIN; EVEROLIMUS; GEMCITABINE; GLYPICAN 3; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 28B; OKT 3; PEGINTERFERON; RAPAMYCIN; RIBAVIRIN; SORAFENIB; SUNITINIB; TELAPREVIR; VASCULOTROPIN;

ACUTE GRAFT REJECTION; ANEMIA; ANTIVIRAL THERAPY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CADAVER DONOR; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL (TOPIC); DRUG DOSE REDUCTION; DRUG WITHDRAWAL; END STAGE LIVER DISEASE; GENE MUTATION; GRAFT FAILURE; GRAFT SURVIVAL; HEPATITIS C; HEPATOGRAPHY; HOSPITAL ADMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; NEUTROPENIA; ORGAN DONOR; OVERALL SURVIVAL; PANCYTOPENIA; PATIENT SELECTION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECURRENT INFECTION; RETRANSPLANTATION; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; UNITED STATES; UNSPECIFIED SIDE EFFECT;

GRAFT SURVIVAL; HEALTH CARE RATIONING; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; LIVING DONORS; RECURRENCE; REOPERATION; TISSUE DONORS; UNITED STATES;

EID: 80052273992     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03587.x     Document Type: Review

References (93)

1. Starzl TE,. The puzzle people: memoirs of a transplant surgeon. Pittsburgh: University of Pittsburgh Press; 1992.
2. Petrowsky H, Busuttil RW,. Evolving surgical approaches in liver transplantation. Semin Liver Dis 2009; 29: 121-133.
3. Cameron AM, Ghobrial RM, Yersiz H, et al,. Optimal utilization of donor grafts with extended criteria: a single-center experience in over 1000 liver transplants. Ann Surg 2006; 243: 748-753; discussion 753-5. (Pubitemid 44297476)
4. Rana A, Hardy MA, Halazun KJ, et al,. Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. Am J Transplant 2008; 8: 2537-2546.
5. Feng S, Goodrich NP, Bragg-Gresham JL, et al,. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6: 783-790. (Pubitemid 43345017)
6. Durand F, Renz JF, Alkofer B, et al,. Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. Liver Transpl 2008; 14: 1694-1707.
7. McCormack L, Petrowsky H, Jochum W, Mullhaupt B, Weber M, Clavien PA,. Use of severely steatotic grafts in liver transplantation: a matched case-control study. Ann Surg 2007; 246: 940-946; Discussion 946-948. (Pubitemid 350179176)
8. Spitzer AL, Lao OB, Dick AA, et al,. The biopsied donor liver: Incorporating macrosteatosis into high-risk donor assessment. Liver Transpl 2010; 16: 874-884.
9. Diamant AL, Babey SH, Wolstein J, Jones M,. Obesity and diabetes: Two growing epidemics in California. Policy Brief UCLA Cent Health Policy Res 2010; PB2010-7: 1-12.
10. Nguyen DM, El-Serag HB,. The epidemiology of obesity. Gastroenterol Clin North Am 2010; 39: 1-7.
11. Lang JD, Jr., Teng X, Chumley P, et al,. Inhaled NO accelerates restoration of liver function in adults following orthotopic liver transplantation. J Clin Invest 2007; 117: 2583-2591. (Pubitemid 47494359)
12. Fondevila C, Hessheimer AJ, Ruiz A, et al,. Liver transplant using donors after unexpected cardiac death: Novel preservation protocol and acceptance criteria. Am J Transplant 2007; 7: 1849-1855. (Pubitemid 46905436)
13. de Rougemont O, Breitenstein S, Leskosek B, et al,. One hour hypothermic oxygenated perfusion (HOPE) protects nonviable liver allografts donated after cardiac death. Ann Surg 2009; 250: 674-683.
14. Guarrera JV, Henry SD, Samstein B, et al,. Hypothermic machine preservation in human liver transplantation: The first clinical series. Am J Transplant 2010; 10: 372-381.
15. Ringe B, Strong RW,. The dilemma of living liver donor death: to report or not to report? Transplantation 2008; 85: 790-793. (Pubitemid 351440741)
16. Ghobrial RM, Freise CE, Trotter JF, et al,. Donor morbidity after living donation for liver transplantation. Gastroenterology 2008; 135: 468-476.
17. Marsh JW, Gray E, Ness R, Starzl TE,. Complications of right lobe living donor liver transplantation. J Hepatol 2009; 51: 715-724.
18. Freise CE, Gillespie BW, Koffron AJ, et al,. Recipient morbidity after living and deceased donor liver transplantation: Findings from the A2ALL Retrospective Cohort study. Am J Transplant 2008; 8: 2569-2579.
19. Ratnera LE, Sandovala PR,. When disaster strikes: Death of a living organ donor. Am J Transplant. 2010; 10: 2577-2581.
20. Yersiz H, Renz JF, Hisatake GM, Farmer DG, Busuttil RW,. The conventional technique in in-situ split-liver transplantation. J Hepatobiliary Pancreat Surg 2003; 10: 11-15. (Pubitemid 36850298)
21. Hong JC, Yersiz H, Farmer DG, et al,. Long-term outcomes for whole and segmental liver grafts in adult and pediatric liver transplant recipients: A 10-year comparative analysis of 2,988 cases. J Am Coll Surg 2009; 208: 682-689; Discusion 689-691.
22. Yersiz H, Renz JF, Farmer DG, Hisatake GM, McDiarmid SV, Busuttil RW,. One hundred in situ split-liver transplantations: A single-center experience. Ann Surg 2003; 238: 496-505; Discussion 506-507.
23. Humar A, Beissel J, Crotteau S, Kandaswamy R, Lake J, Payne W,. Whole liver versus split liver versus living donor in the adult recipient: An analysis of outcomes by graft type. Transplantation 2008; 85: 1420-1424.
24. Renz JF, Emond JC, Yersiz H, Ascher NL, Busuttil RW,. Split-liver transplantation in the United States: Outcomes of a national survey. Ann Surg 2004; 239: 172-181. (Pubitemid 38176350)
25. Merion RM, Pelletier SJ, Goodrich N, Englesbe MJ, Delmonico FL,. Donation after cardiac death as a strategy to increase deceased donor liver availability. Ann Surg 2006; 244: 555-562.
26. de Vera ME, Lopez-Solis R, Dvorchik I, et al,. Liver transplantation using donation after cardiac death donors: long-term follow-up from a single center. Am J Transplant 2009; 9: 773-781.
27. Jay CL, Lyuksemburg V, Kang R, et al,. The increased costs of donation after cardiac death liver transplantation: caveat emptor. Ann Surg 2010; 251: 743-748.
28. Mathur AK, Heimbach J, Steffick DE, Sonnenday CJ, Goodrich NP, Merion RM,. Donation after cardiac death liver transplantation: Predictors of outcome. Am J Transplant 2010; 10: 2512-2519.
29. Hashimoto K, Eghtesad B, Gunasekaran G, et al,. Use of tissue plasminogen activator in liver transplantation from donation after cardiac death donors. Am J Transplant 2010; 10: 2665-2672.
30. Berg CL, Steffick DE, Edwards EB, et al,. Liver and intestine transplantation in the United States 1998-2007. Am J Transplant 2009; 9 (Pt 2): 907-931.
31. Ghobrial RM, Steadman R, Gornbein J, et al,. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001; 234: 384-393; discussion 393-4.
32. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR,. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-896. (Pubitemid 34267271)
33. Berenguer M,. What determines the natural history of recurrent hepatitis C after liver transplantation? J Hepatol 2005; 42: 448-456. (Pubitemid 40342920)
34. Berenguer M, Prieto M, Rayon JM, et al,. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32 (Pt 1): 852-858.
35. Berenguer M, Lopez-Labrador FX, Wright TL,. Hepatitis C and liver transplantation. J Hepatol 2001; 35: 666-678. (Pubitemid 33078280)
36. Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M,. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8: 679-687. (Pubitemid 351287553)
37. Charlton M, Seaberg E, Wiesner R, et al,. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823-830. (Pubitemid 28405436)
38. Roche B, Samuel D,. Risk factors for hepatitis C recurrence after liver transplantation. J Viral Hepat 2007; 14 (Suppl 1): 89-96. (Pubitemid 47624117)
39. Gane EJ, Naoumov NV, Qian KP, et al,. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110: 167-177. (Pubitemid 26021616)
40. Beckebaum S, Iacob S, Klein CG, et al,. Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients. Transplantation 2010; 89: 983-993.
41. Cabrera R, Tu Z, Xu Y, et al,. An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004; 40: 1062-1071. (Pubitemid 39425561)
42. Carpentier A, Conti F, Stenard F, et al,. Increased expression of regulatory Tr1 cells in recurrent hepatitis C after liver transplantation. Am J Transplant 2009; 9: 2102-2112.
43. Perrella A, Arenga G, Pisaniello D, et al,. Elevated CD4+/CD25+ T cell frequency and function during hepatitis C virus recurrence after liver transplantation. Transplant Proc 2009; 41: 1761-1766.
44. Miroux C, Vausselin T, Delhem N,. Regulatory T cells in HBV and HCV liver diseases: implication of regulatory T lymphocytes in the control of immune response. Expert Opin Biol Ther 2010; 10: 1563-1572.
45. Bahra M, Neumann UP, Jacob D, Langrehr JM, Neuhaus P,. Repeated steroid pulse therapies in HCV-positive liver recipients: Significant risk factor for HCV-related graft loss. Transplant Proc 2005; 37: 1700-1702. (Pubitemid 40790801)
46. Charlton M, Seaberg E,. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: Results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999; 5 (4 Suppl 1): S107-S114. (Pubitemid 29321242)
47. Berenguer M, Aguilera V, Prieto M, et al,. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006; 44: 717-722.
48. Berenguer M, Aguilera V, San Juan F, et al,. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. Transplantation 2010; 90: 1204-1209.
49. Rayhill SC, Barbeito R, Katz D, et al,. A cyclosporine-based immunosuppressive regimen may be better than tacrolimus for long-term liver allograft survival in recipients transplanted for hepatitis C. Transplant Proc 2006; 38: 3625-3628. (Pubitemid 44908427)
50. Villamil F, Levy G, Grazi GL, et al,. Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine. Transplant Proc 2006; 38: 2964-2967. (Pubitemid 44737930)
51. Miroux C, Morales O, Carpentier A, et al,. Inhibitory effects of cyclosporine on human regulatory T cells in vitro. Transplant Proc 2009; 41: 3371-3374.
52. Duclos-Vallee JC, Feray C, Sebagh M, et al,. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008; 47: 407-417. (Pubitemid 351280708)
53. de Vera ME, Dvorchik I, Tom K, et al,. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 2006; 6: 2983-2993.
54. Roland ME, Barin B, Carlson L, et al,. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant 2008; 8: 355-365.
55. Coto-Llerena M, Pérez-Del-Pulgar S, Crespo G, et al,. Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. Am J Transplant 2011; 11: 1051-1057.
56. Lange CM, Moradpour D, Doehring A, et al,. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol 2010; in press.
57. Sheiner PA, Boros P, Klion FM, et al,. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998; 28: 831-838. (Pubitemid 28405437)
58. Peveling-Oberhag J, Zeuzem S, Hofmann WP,. Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation. Med Microbiol Immunol 2010; 199: 1-10.
59. Shergill AK, Khalili M, Straley S, et al,. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005; 5 (1): 118-124. (Pubitemid 40095135)
60. Saab S, Oh MK, Ibrahim AB, et al,. Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C. Liver Transpl 2007; 13: 1032-1038. (Pubitemid 47177137)
61. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
62. Fukuhara T, Taketomi A, Motomura T, et al,. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 1577-1585, 1585.e1-3.
63. Charlton MR, Thompson A, Veldt BJ, et al,. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53: 317-324.
64. Bizollon T, Pradat P, Mabrut JY, et al,. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant 2005; 5: 1909-1913. (Pubitemid 41039864)
65. Berenguer M,. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-287.
66. Picciotto FP, Tritto G, Lanza AG, et al,. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46: 459-465. (Pubitemid 46185706)
67. Veldt BJ, Poterucha JJ, Watt KD, et al,. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant 2008; 8: 2426-2433.
68. Kwo PY, Lawitz EJ, McCone J, et al,. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705-716.
69. McHutchison JG, Everson GT, Gordon SC, et al,. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
70. Chak E, Saab S,. Pegylated interferon and ribavirin dosing strategies to enhance sustained virologic response. Curr Hepat Rep 2010; 9: 147-154.
71. Bellido CB, Martinez JM, Gomez LM, et al,. Indications for and survival after liver retransplantation. Transplant Proc 2010; 42: 637-640.
72. Verna EC, Brown RS, Jr,. Hepatitis C and liver transplantation: Enhancing outcomes and should patients be retransplanted. Clin. Liver Dis 2008; 12: 637-659, ix-x. (Pubitemid 351952468)
73. Markmann JF, Gornbein J, Markowitz JS, et al,. A simple model to estimate survival after retransplantation of the liver. Transplantation 1999; 67: 422-430. (Pubitemid 29094015)
74. Lacey M,. Arizona cuts financing for transplant patients. The New York Times December 3, 2010: A1.
75. Liu H, Li P, Zhai Y, et al,. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol 2010; 16: 4410-4415.
76. Ringe B, Wittekind C, Bechstein WO, Bunzendahl H, Pichlmayr R,. The role of liver transplantation in hepatobiliary malignancy. A retrospective analysis of 95 patients with particular regard to tumor stage and recurrence. Ann Surg 1989; 209: 88-98. (Pubitemid 19044215)
77. Iwatsuki S, Starzl TE, Sheahan DG, et al,. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991; 214: 221-228; Discussion 228-229.
78. Mazzaferro V, Regalia E, Doci R, et al,. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699. (Pubitemid 26079803)
79. Yao FY, Ferrell L, Bass NM, et al,. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403. (Pubitemid 32496976)
80. Duffy JP, Vardanian A, Benjamin E, et al,. Liver transplantation criteria for hepatocellular carcinoma should be expanded: A 22-year experience with 467 patients at UCLA. Ann Surg 2007; 246: 502-509; Discussion 509-511. (Pubitemid 47312148)
81. Bhoori S, Toffanin S, Sposito C, et al,. Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: A proof of principle. J Hepatol 2010; 52: 771-775.
82. Lee JS, Heo J, Libbrecht L, et al,. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006; 12: 410-416.
83. Ho MC, Lin JJ, Chen CN, et al,. A gene expression profile for vascular invasion can predict the recurrence after resection of hepatocellular carcinoma: a microarray approach. Ann Surg Oncol 2006; 13: 1474-1484.
84. Kaseb AO, Hassan MM, Lin E, et al,. V-CLIP: integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. Cancer 2011; in press.
85. Llovet JM, Ricci S, Mazzaferro V, et al,. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
86. Cheng AL, Kang YK, Chen Z, et al,. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
87. Huynh H, Ngo VC, Choo SP, et al,. Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma. Curr Cancer Drug Targets. 2009; 9: 738-747.
88. Zhu AX, Sahani DV, Duda DG, et al,. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009; 27: 3027-3035.
89. Faivre S, Raymond E, Boucher E, et al,. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: An open-label, multicentre, phase II study. Lancet Oncol 2009; 10: 794-800.
90. Zimmerman MA, Trotter JF, Wachs M, et al,. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 2008; 14: 633-638. (Pubitemid 351696274)
91. Bilbao I, Sapisochin G, Dopazo C, et al,. Indications and management of Everolimus after liver transplantation. Transplant Proc 2009; 41: 2172-2176.
92. Lee TK, Han JS, Fan ST, et al,. Gene delivery using a receptor-mediated gene transfer system targeted to hepatocellular carcinoma cells. Int J Cancer 2001; 93: 393-400. (Pubitemid 32592059)
93. Yamada T, Iwasaki Y, Tada H, et al,. Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nat Biotechnol 2003; 1: 885-890. Available at:. Accessed December 2010. (Pubitemid 36936193)